Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer
Edward H. Romond(NSABP Foundation), Norman Wolmark(NSABP Foundation)
Cited by 5,349
Related Papers
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
Randomized Phase II Study Evaluating Palbociclib in Addition to Letrozole as Neoadjuvant Therapy in Estrogen Receptor–Positive Early Breast Cancer: PALLET Trial
|Journal of Clinical Oncology|2018|233
Matched cohort study of germline BRCA mutation carriers with triple negative breast cancer in brightness
|npj Breast Cancer|2021|37